Department of Medicine, VA San Diego Healthcare System, San Diego, CA, USA; University of California, San Diego, CA, USA.
J Sex Med. 2014 Feb;11(2):563-73. doi: 10.1111/jsm.12368. Epub 2013 Nov 6.
Testosterone (T) administration to men increases T, estradiol (E2), dihydrotestosterone (DHT), and fat-free mass (FFM), and decreases fat mass (FM) but does not consistently improve insulin sensitivity (IS).
The aim of this study was to examine the effects of T administration in obese, nondiabetic men on body composition and IS, and to determine if inhibition (i) of metabolism of T to E2 with anastrazole or to DHT with dutasteride alters these effects.
This was a 98-day randomized, double-blind, parallel group, placebo-controlled trial of 57 men, 24-51 year, free T in the lower 25% of normal range (<0.33 nmol/L), body mass index ≥ 30.0 kg/m(2). Subjects were randomized to one of four groups: (i) placebo: gel, pills, and injection; (ii) T/DHT/iE2: T gel, anastrazole, and acyline (gonadotropin releasing-hormone antagonist to suppress endogenous T); (iii) T/iDHT/E2: T gel, dutasteride, and acyline; (iv) T/DHT/E2: T gel, placebo pills, and acyline.
Main outcome measures are insulin sensitivity as percent change (%Δ) in glucose disposal rates (GDR) from a two-step euglycemic clamp (GDR1 and 2), and %FM and %FFM by dual X-ray absorptiometry scan.
Insulin Sensitivity: %Δ GDR1 differed across groups (P = 0.02, anova) and was significantly higher in the dutasteride (T/iDHT/E2) compared with the placebo and T gel (T/DHT/E2) groups. %ΔGDR2 was higher in the dutasteride (T/iDHT/E2) compared with the anastrazole (T/DHT/iE2) group. Body Composition: T gel alone (T/DHT/E2) or with dutasteride (T/iDHT/E2) significantly increased %FFM (P < 0.05) and decreased %FM (P < 0.05). There was no change in %FFM or %FM after placebo or anastrazole (T/DHT/iE2).
The combination of T plus dutasteride improved body composition and IS while T alone improved body composition but not IS, suggesting that when T is administered to men, reduction to DHT attenuates the beneficial effects of aromatization to E2 on IS but not body composition.
给予男性睾丸酮(T)会增加 T、雌二醇(E2)、二氢睾丸酮(DHT)和去脂体重(FFM),减少脂肪量(FM),但并不总能改善胰岛素敏感性(IS)。
本研究旨在探讨睾丸酮在肥胖、非糖尿病男性中的应用对身体成分和 IS 的影响,并确定 T 向 E2 的代谢抑制(用阿那曲唑)或向 DHT 的代谢抑制(用度他雄胺)是否会改变这些作用。
这是一项为期 98 天的随机、双盲、平行分组、安慰剂对照试验,共纳入 57 名年龄在 24-51 岁、游离 T 在正常范围下限的 25%以下(<0.33nmol/L)、体重指数(BMI)≥30.0kg/m2 的男性。受试者随机分为四组:(i)安慰剂组:凝胶、药丸和注射剂;(ii)T/DHT/iE2 组:睾丸酮凝胶、阿那曲唑和 acyline(促性腺激素释放激素拮抗剂,抑制内源性 T);(iii)T/iDHT/E2 组:睾丸酮凝胶、度他雄胺和 acyline;(iv)T/DHT/E2 组:睾丸酮凝胶、安慰剂药丸和 acyline。
主要观察指标是通过两步血糖钳夹试验(GDR1 和 2)得到的葡萄糖摄取率(GDR)的百分比变化(%Δ),以及双能 X 线吸收法扫描得到的去脂体重(FFM)和脂肪量(FM)的百分比变化。
胰岛素敏感性:各组间%ΔGDR1 存在差异(P=0.02,方差分析),且 dutasteride(T/iDHT/E2)组明显高于安慰剂组和 T 凝胶(T/DHT/E2)组。%ΔGDR2 在 dutasteride(T/iDHT/E2)组高于 anastrazole(T/DHT/iE2)组。身体成分:单独使用 T 凝胶(T/DHT/E2)或与度他雄胺(T/iDHT/E2)合用可显著增加 FFM(P<0.05)和减少 FM(P<0.05)。安慰剂或 anastrazole(T/DHT/iE2)组的 FFM 和 FM 百分比均无变化。
T 加度他雄胺联合治疗可改善身体成分和 IS,而 T 单独治疗仅改善身体成分而不改善 IS,这表明当给予男性 T 时,向 DHT 的转化减少会削弱芳香化向 E2 的转化对 IS 的有益作用,但不会改变身体成分。